Institut Andrée Dutreix

What Institut Andrée Dutreix does

Institut Andrée Dutreix is a private integrated cancer center headquartered at 891 avenue de Rosendaël in Dunkerque, France, serving the Nord Littoral and Maritime Flanders healthcare territory (Dunkerque, Calais, Saint-Omer, Hazebrouck). Named after Andrée Dutreix — France's first hospital medical physicist, hired in 1953 and co-creator of the specialized diploma in radiological physics in 1970 — the center operates as the only integrated cancer facility in the region, delivering radiotherapy, medical oncology, chemotherapy, nuclear medicine (scintigraphy and PET scans via Nord TEP de Lille), and supportive care (psychology, dietetics, adapted physical activity, aesthetic care, complementary medicine) across two sites: the main Dunkerque facility and the Centre d'Oncologie Médicale Nord Littoral at Clinique de Flandre in Coudekerque-Branche. The center maintains a 24/7 emergency service and a clinical research program attached to the StARCC network led by GIRCI Nord-Ouest spanning 68 healthcare establishments across Hauts-de-France and Normandy.

The technical stack centers on high-precision radiotherapy, anchored by two Varian TrueBeam particle accelerators (the first installed north of Paris, part of a full equipment renewal since 2017), a GE Healthcare Discovery CT scanner for simulation and dosimetry, a Varian PerfectPitch 6DoF treatment table, Vision RT surface-guided radiotherapy certified in February 2025 for tattoo-free positioning, and TheraPanacea AI-based contouring for treatment planning. Clinical capabilities include IMRT, IGRT, stereotactic radiotherapy (introduced 2020 for pulmonary and cerebral lesions, expanded to vertebral indications in 2024), and Deep Inspiration Breath Hold (DIBH) for cardiac-sparing left-sided breast cancer radiotherapy. Regulatory authorizations include ASN possession-and-use permits for particle accelerators and a simulation scanner (renewed for stereotactic treatments in March 2020 and July 2022) and ARS authorization to practice cancer treatment (renewed November 2019).

The revenue model is reimbursement-driven through the French national health insurance system (Sécurité sociale), with cancer treatment covered at 100% under the ALD (Affection Longue Durée) framework at regulated public tariffs (€55 first consultation, €30 follow-up). Patient acquisition is referral-based from the territorial physician network with no commercial go-to-market motion. The institution employs approximately 14 staff, operates as an SELAS per management team references, and displays an Elsan logo on the website whose corporate relationship is not explicitly characterized. Revenue is not publicly disclosed and no funding rounds or external investment have been identified in the source material.

Name

Institut Andrée Dutreix

Legal name

Institut Andrée Dutreix

Website

https://institut-andree-dutreix.fr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Institut Andrée Dutreix is a private integrated cancer center in Dunkerque, France, serving the Nord Littoral and Maritime Flanders territory with high-precision radiotherapy, chemotherapy, nuclear medicine, and supportive care across two sites, reimbursed via the French public health insurance system.

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Urologic Oncology (HLAKAOAB)

Keywords

• Cancer treatment services
• Radiotherapy services
• Medical oncology care
• Nuclear medicine imaging
• Clinical research trials

Headquarters

HQ city

Dunkerque

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Public Health Insurance (Sécurité sociale): As a public healthcare institution, the primary revenue stream is reimbursement through the French national health insurance system (Sécurité sociale). Cancer treatment is covered at 100% under the ALD (Affection Longue Durée) framework. Consultations are billed at regulated public tariffs: 55€ for first consultation, 30€ for follow-up consultation.
2. Complementary Insurance (Mutuelle): Patients with supplementary insurance (mutuelle) receive reimbursement for covered portions of treatment costs. Transport costs and certain treatments (e.g., heel spur radiotherapy) may involve additional patient co-pays billed via standard healthcare billing.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Institut Andrée Dutreix is an integrated cancer treatment center located in Dunkerque, France, providing radiotherapy, chemotherapy, targeted therapy, and nuclear medicine services to cancer patients across the Nord Littoral and Maritime Flanders territory. The institute operates across two physical sites (the main Dunkerque center and the medical oncology unit at Clinique de Flandre in Coudekerque-Branche) and delivers disease-specific treatment programs for breast, lung, prostate, bladder, gynecological, digestive, brain, and ENT cancers, alongside supportive care services and clinical trial access.

Product overview

Institut Andrée Dutreix is an integrated cancer center in Dunkerque, Nord Littoral, comprising three main facilities: the Centre de Cancérologie et Radiothérapie Nord Littoral (equipped with two Varian particle accelerators and a GE Healthcare CT scanner), the Centre de Médecine Nucléaire Nord Littoral (for scintigraphy and PET scan), and the Centre d'Oncologie Médicale Nord Littoral at Clinique de Flandre (for chemotherapy). The center offers comprehensive cancer treatment services including radiotherapy (with advanced techniques like stereotactic radiotherapy and DIBH), chemotherapy, targeted therapies, and supportive care services such as psychology, dietetics, adapted physical activity, and aesthetic care through the Maison des Soins de Support des Flandres facility. Treatment is provided for multiple cancer types including breast, bladder, lung, prostate, gynecological, digestive, brain, and ENT cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• Centre de Cancérologie et Radiothérapie Nord Littoral
• Centre de Médecine Nucléaire Nord Littoral
• Centre d'Oncologie Médicale Nord Littoral (Clinique de Flandre)
• Radiotherapy
• Stereotactic Radiotherapy
• Deep Inspiration Breath Hold (DIBH)
• Tattoo-Free Radiotherapy (Vision RT)
• Chemotherapy
• Targeted Therapies
• Clinical Research
• Maison des Soins de Support des Flandres
• Low-Level Laser Therapy (Photobiomodulation)
• Cancer Treatment Programs

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• GIRCI Nord-OuestcoreStrategic or Co-development Partner · 1 September 2018The Groupement Interrégional de Recherche Clinique et d'Innovation (GIRCI) Nord-Ouest leads the StARCC initiative (Structuration de l'Activité de Recherche Clinique en Cancérologie) with ARS Hauts-de-France and Normandy support. Institut Andrée Dutreix joined StARCC in September 2018. The initiative deploys mobile clinical research teams across 68 establishments to increase clinical trial inclusions and access to therapeutic innovation.
• Nord TEP de LillecoreStrategic or Co-development PartnerPartnership with Nord TEP de Lille for PET scan (Tomographie par Émission de Positons) services. The Centre de Médecine Nucléaire Nord Littoral at Institut Andrée Dutreix performs PET scans in partnership with Nord TEP de Lille, providing complementary diagnostic imaging for cancer staging and treatment planning.
• Centre Hospitalier de la Région de Saint-OmerminorStrategic or Co-development PartnerCollaboration between Institut Andrée Dutreix Dunkerque and Centre Hospitalier de la Région de Saint-Omer announced in February 2024. This collaboration extends the network of cancer care services in the territory.
• DK PulseminorChannel Partner/ Reseller/ DistributorDK Pulse, a Maison du Sport Santé in Dunkerque, partners with the institute to provide Adapted Physical Activity (APA) programs for cancer patients at Clinique de Flandre on Tuesdays and Fridays. DK Pulse also operates APA Complex at the Malo-les-Bains dike and is affiliated with the Maison Sport Santé Pas'Apa in Eperlecques.
• ElsancoreStrategic or Co-development PartnerElsan is the parent private hospital group that includes Clinique de Flandre. The Institut Andrée Dutreix, while an independent center, works closely with Elsan facilities including Clinique de Flandre for chemotherapy administration and medical oncology services.
• Varian (Siemens Healthineers)coreTechnology or IntegrationVarian (a Siemens Healthineers company) supplies the TrueBeam particle accelerator (first installed north of Paris) and the PerfectPitch 6DoF treatment table. Institut Andrée Dutreix renewed all radiotherapy equipment since 2017, positioning itself as equivalent to Centre Oscar Lambret in Lille.
• GE HealthcarecoreTechnology or IntegrationGE Healthcare supplies the Discovery CT scanner dedicated to radiotherapy simulation, virtual centering, and computerized dosimetry for 3D conformal radiotherapy.
• Vision RTcoreTechnology or IntegrationVision RT (UK-based company) provides the Align RT surface-guided radiotherapy system enabling tattoo-free treatment positioning. Institut Andrée Dutreix received Vision RT certification in February 2025. The system uses stereo 3D cameras and sensors for real-time treatment guidance and automatically halts treatment if positioning or breathing is suboptimal.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Others

• Elsan: Leading French private hospital group whose logo appears on the Institut Andrée Dutreix website. Clinique de Flandre, where the institute administers chemotherapy, is an Elsan facility, making Elsan a critical infrastructure partner and the closest corporate counterparty.

Direct peers

• Centre Pierre Curie (Beuvry): Non-profit cancer center in Beuvry (Béthune area) offering chemotherapy and radiotherapy. Its proximity to Dunkerque in northern Hauts-de-France and similar equipment set makes it a directly comparable regional peer.
• Centre Oscar Lambret: CLCC comprehensive cancer center in Lille, Hauts-de-France, offering radiotherapy, chemotherapy, and supportive care. Frequently cited by Institut Andrée Dutreix as the regional reference center for complex cases and where some of its own physicians previously trained.
• Centre François Baclesse: CLCC cancer center in Caen, Normandy, offering radiotherapy, medical oncology, and a clinical research program. Affiliated with the same regional clinical research inter-region, making it a peer on both clinical and operational dimensions.
• Institut de Cancérologie de Lorraine: CLCC cancer center in Nancy-Vandœuvre-lès-Nancy providing radiotherapy, medical oncology, and supportive care. Dr. Aisenfarb previously served there as Chef de Clinique, demonstrating direct career overlap with the Institut Andrée Dutreix team.
• Centre Eugène Marquis: CLCC cancer center in Rennes, Brittany, providing multidisciplinary oncology care including radiotherapy, chemotherapy, and clinical research. A useful comparable for the scale and operational model of a mid-sized French cancer center.
• Centre Léon Bérard: CLCC cancer center in Lyon combining care, research, and teaching. Comparable in offering integrated oncology services including stereotactic radiotherapy and clinical trials, though at larger scale.
• Institut de Cancérologie de l'Ouest: CLCC cancer center with sites in Angers and Nantes, delivering radiotherapy, chemotherapy, surgery, and supportive care. Comparable in offering a multi-site integrated care model targeting a defined regional catchment.
• Centre Marie Curie (Arras): Regional oncology and radiotherapy center in Arras, Pas-de-Calais. Multiple Institut Andrée Dutreix physicians (Dr. Boughzala-Bennadji, Dr. Prades) previously practiced there, indicating a comparable service model and patient catchment profile.

Broad incumbents

• Unicancer: Federation of the 18 French CLCC comprehensive cancer centers. While not a direct competitor, it sets clinical, quality, and research standards for the segment in which Institut Andrée Dutreix operates, and links the institute indirectly to the broader F-SIRIC and StARCC ecosystems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/radiotherapiedunkerque
• LinkedInlinkedin.com/company/institut-andr%C3%A9e-dutreix

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Andrée Dutreix